Sanofi (SNY) Equity Income (2009 - 2026)

Sanofi has disclosed Equity Income across 18 years of filings, most recently posting -$10.5 million for Q2 2026.

• In Q2 2026, Equity Income fell 121.49% year-over-year to -$10.5 million; the TTM figure through Jun 2026 stood at $437.0 million (up 160.63% YoY), while the FY2025 annual figure was $337.6 million, up 280.36% from the prior year.
• Equity Income came in at -$10.5 million for Q2 2026 at Sanofi, down from $12.9 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $337.6 million in Q4 2025 to a low of -$69.7 million in Q2 2023.
• Average Equity Income over 5 years is $58.2 million, with a median of $31.8 million recorded in 2022.
• Year-over-year, Equity Income plunged 462.68% in 2024 and soared 6418.06% in 2025.
• Over 5 years, Equity Income stood at $66.3 million in 2022, then soared by 375.38% to $315.3 million in 2023, then sank by 101.69% to -$5.3 million in 2024, then soared by 6418.06% to $337.6 million in 2025, then plunged by 103.1% to -$10.5 million in 2026.
• Per Business Quant data, the three most recent Equity Income figures were -$10.5 million in Q2 2026, $12.9 million in Q1 2026, and $337.6 million in Q4 2025.